Thanks, Danilo.
revenue, mentioned previously, XX% pharma a portfolio year our XXXX of global to of cash a strong in multiple increase partnerships, long-term expansion As operational and a a with product debt-free balance to-date reduction cash great additional sheet. continues with new a in XX% execution launches, be position burn year-over-year
that break into progress let's with growth on We always, our had quarter numerous terrific X and As Delivery. down Biologics Drug pillars. #X, fronts. Starting a pillar
in Let's and recent talk milestones therapy cell gene about key X business. our
increase as it is pathway. regulatory advancing shows we who product partners significant in to along sales of important progression the This pharma saw are as Danilo very our First, actual partners. mentioned, a the
revenue. heavily weighted service Our early engagement with pharma is normally towards
discovery studies, and Later testing, higher outpace eventually benchtop commercialization have in sales where we generally and partners generally to studies where biopharma trials, this limited is data analysis demonstrates with move progression see strategy process. we or product sales sales the discussions, through that consultancy, engagement, which into hospital products. begin and post-procedural nonclinical clinical the pilot generally infusion regulatory supporting is the product We service partners of continued This and actual purchasing navigation service and our sales.
pathways referred partners new-to-world to Second, the selected we have cell regulatory execution seen to of speed eventual trial now therapies and clinical these for designed often various accelerated gene regenerative approval and as multiple therapies. FDA
the that the and programs importance either gene these entire the have may designated have FDA Track placed partnered market or and Review, recognition highlights which cell to X the impact Priority life-altering as patients. drugs has RMAT, therapy Fast been have now that of on We that the
and and accelerated of While FDA pathways results the programs there clinical time it has is approval, demonstrated never these eligible progress the in guarantee exciting that very be created our or have of for first is that place. a line partners reassuring enough to and significant these many
these alone, in included total millions prevalence the we In are together programs is the if indications added that patients expedited of of total, the measured all globally. patient now in
and and goal the to expanding Third, our with to GLP our studies services driven in ClearPoint with stage commence GLP preclinical we continue ready be progress XXXX. initial capacity make later to next
not for GLP-compliant continues believe facilities procedures expertise. very as team to well This feel our future. the as and ability execute our confident larger in the services products Our and demand our under studies further unique to We in near in potential the also provide, evolution our long-term pharmaceutical continue stronger and the earlier just delivery the will that of services. the even with continuum to but of industry through expand build we relationships in drug to in structured business value
excited our therapy These on frameworks community. the And that with demonstrate are pharma, fourth, how strategic to we also speaking in that and have on of valued frameworks that partner. unique collaborate based provide proving agreements we are desired now we and our biopharma can individual each the executed share flexibility do, our fact, creativity those capabilities of needs cell gene by relationships all of we across
But all what These information. or We and different agreements, have that revenue provide specific pricing one, pays can be development obviously in their X individual X. successfully confidential now number where of is a and strategic a co-development our development ClearPoint signed sometimes cannot share device combination of representing I structures can milestones to the for be or development used trials. delivery custom that to fee preclinical a partner will software we clinical and
once the commercial with Neuro the the pricing, in provide instead to to selling directly their a the a purchase FDA devices simplify hospitals. Number two, product of to approved delivery from the where Neuro partner kit drug ClearPoint intends ClearPoint commercial technology and of ClearPoint product
device at receives pricing. is therapy Neuro pricing three, its compared to a when pathway. regulatory payments trial Number commercial through clinical milestones, progression and cash ClearPoint clinical nonclinical upon The of a whereby premium
in IND of approval granted first example, study enrolled patient trial. For FDA an IDE the by or or the the
discovery commercial these and do can process very drug not at the the to happen place a with Importantly, end and have milestones regulatory during approval. take
gene royalty gene sales a is -- delivered or itself ClearPoint delivery devices. on ClearPoint finally, of the drug based using on payment And the commercial which cell Neuro therapy, to
drugs we European as likely X-world reminder, ClearPoint be new approved. the it while Neuro catheters neuro assured, therapy approved canalis a have seen combination Union that first the with for in gene As will devices not we believe these very is the as
partners. an becomes company, our Our to essential supplier therefore, pharma
device. looking price earn very disposable Neuro's unique even for of that position and manufacturing single and intellectual to future As partnership of increased the and us partners to in property, our our services revenues result, a are access long-term a It agreements need assurances simply for is more. long-term products of ClearPoint beyond redundancy a this supply, unique puts
saw well on Neurosurgery We of scanners the the or #X, continuation by CT designed system with of to as Navigation. placements OR operating quarter, customer sales release product Pillar activations which site full use our navigation traditional and accelerated for market our the and SmartFrame MRI-guided system operating of both Moving room in as in fueled continued is room. the
place in seen developments DDS that We space quarter. exciting the very third X have also the took in
the on the based got our evidence comfortably of approval, are wealth for a DBS Medtronic sleep procedures asleep achieved First, for labeling these patient outcomes wake a when excellent compelling approved is clinical DBS procedures. that versus
a to labeling was large without FDA which Medtronic on new labeling patients allow technique, begin educating the This this like will historically. new not company possible
the announced depression. severe has treat to designed that is Abbott Second, TRANSCEND to use of DBS study, the which study
take it that will they study ClearPoint new years to plan indication participating use While as of achieved, many XXX communicated and the will likely before enroll preferred TRANSCEND technology us is centers navigation itself system. have patients their the this to
of ClearPoint This and patients very involved beginning these will new to trial indication. this from also participate allow in the be
approximately we each historically activated X a new reminder, year. have to X customers As
more for that of this X XX the up earnings third XX the year in at than quarter, total the here that time call. this added brings With to actually we and our
the fuel accelerated had X and sales, versus service sales, communicated this about we earlier year global but end XXX product have placements only second, sites But achieving XXXX, not than our an achieve which new We of first talk capital, also pace of we placements, goal not which XXXX. will we sooner. more if doubled by helped a by will half given the rental ago. of activated XXX disposable of These in believe
our opened the In existing Access Next, of clearance obtained let's to second quarter, move some on Products. which FDA accessory PRISM the robotic we that door in navigation Anchor with prefer systems of and system the for Bolt Therapy for use sites which the PRISM robotic Navigation. laser use has our to place ClearPoint is at pillar #X,
us comfortably approval to into they adoption, mechanisms in make few doing product iterating of by show additional fit and adoption we customers new seem with are as can but are new third as the needing to not important devices put PRISM get released anchoring their simple, and steps These to we listening their that quarter, they to we quickly quicker workflow to can everything our existing and feedback, compatibility releases third-party Here to hospital possible. changes the access help VAC new through hospital's ancillary hospitals with that packaging may process.
While for our of XXXX. for -- anticipate do half in busy we currently while are as remain is about X we develop approval, us today available to we system we pathway hospitals scanners, are target laser plenty somewhat of the becoming limited market scanner there which to X.X only approved do the regulatory keep
We current power than believe MRI tool partner, designed to potential to will meaningfully times. our faster are conditional products. commercialize significantly able to therapy is surgeons which our drill to the provide an also making for significant has access reduce we Medical, powerful and being progress be drill, our This a complement and developed by procedure hand toward access
exclusive is product. the worldwide drill commercialization, the Once Neuro be ready for for development finalized will new distributor ClearPoint this is and
report neurosurgery therapy, navigation we and into bucket medical for disposables. Now we when device together numbers them
mentioned, driven in XX% the navigation, room quarter X again from revenue and by is sources: navigation operating therapy. this Danilo MRI segment -- disposable and grew As laser
margin Overall, to our once sales our the which at again increased more on positive factory. gross a due year doubled has ago, versus than a impact throughput product
quarter cash is Finally, saw reducing XXXX. achieving was burn that a XX% only This Pillar operational scale while to disciplined global profitability. of growth XX% represents standpoint revenue down and in QX #X, let's versus a talk $X.X which a which spending reduction million, another about from
future our our driving breakeven equivalents position cash have only our and we'll end in in XXXX of needs retiring our By growth. We a that today any continue capital $XX.X quarter, feel quarter the review on we to profitable significant debt the no and the sheet. in believe cash cash with and capital balance possible, outstanding context debt to planning we and strong optionality service that is million over by flow cash of
$XX guidance to of our $XX and growth the XX% believe year. year XX% between the million that for million, previous continue of will full fall to We revenue full between our representing for
call I that, the up to With will any open now questions.
